Kamada Gestione

Gestione criteri di controllo 3/4

Kamada Il CEO è Amir London, nominato in Jul2015, e ha un mandato di 9.33 anni. la retribuzione annua totale è $ 861.00K, composta da 47.5% di stipendio e 52.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.1% delle azioni della società, per un valore di ₪ 1.26M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.4 anni e 4.9 anni.

Informazioni chiave

Amir London

Amministratore delegato

US$861.0k

Compenso totale

Percentuale dello stipendio del CEO	47.5%
Mandato del CEO	9.3yrs
Proprietà del CEO	0.1%
Durata media del management	2.4yrs
Durata media del Consiglio di amministrazione	4.9yrs

Aggiornamenti recenti sulla gestione

Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year

Dec 22

We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed

Dec 16

Recent updates

Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business

Nov 20

Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality

Mar 14

Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%

Dec 30

Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year

Dec 22

Is Kamada (TLV:KMDA) Using Too Much Debt?

Jan 26

We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed

Dec 16

Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%

Mar 01

Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?

Feb 08

Is Weakness In Kamada Ltd. (TLV:KMDA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Jan 21

Kamada Ltd. (TLV:KMDA) Shares Could Be 42% Below Their Intrinsic Value Estimate

Jan 03

How Many Kamada Ltd. (TLV:KMDA) Shares Have Insiders Sold, In The Last Year?

Dec 15

Are Kamada's (TLV:KMDA) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 29

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Amir London rispetto agli utili di Kamada?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$16m
Jun 30 2024	n/a	n/a	US$15m
Mar 31 2024	n/a	n/a	US$12m
Dec 31 2023	US$861k	US$409k	US$8m
Sep 30 2023	n/a	n/a	US$6m
Jun 30 2023	n/a	n/a	US$3m
Mar 31 2023	n/a	n/a	-US$2m
Dec 31 2022	US$684k	US$410k	-US$2m
Sep 30 2022	n/a	n/a	-US$10m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$663k	US$412k	-US$2m
Sep 30 2021	n/a	n/a	US$4m
Jun 30 2021	n/a	n/a	US$12m
Mar 31 2021	n/a	n/a	US$15m
Dec 31 2020	US$840k	US$406k	US$17m
Sep 30 2020	n/a	n/a	US$21m
Jun 30 2020	n/a	n/a	US$20m
Mar 31 2020	n/a	n/a	US$23m
Dec 31 2019	US$738k	US$333k	US$22m
Sep 30 2019	n/a	n/a	US$35m
Jun 30 2019	n/a	n/a	US$26m
Mar 31 2019	n/a	n/a	US$26m
Dec 31 2018	US$549k	US$327k	US$22m
Sep 30 2018	n/a	n/a	US$11m
Jun 30 2018	n/a	n/a	US$13m
Mar 31 2018	n/a	n/a	US$12m
Dec 31 2017	US$525k	US$293k	US$7m

Compensazione vs Mercato: La retribuzione totale di Amir ($USD 861.00K ) è circa la media per le aziende di dimensioni simili nel mercato IL ($USD 792.67K ).

Compensazione vs guadagni: La retribuzione di Amir è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Amir London (55 yo)

9.3yrs

Mandato

US$861,000

Compensazione

Mr. Amir London has been the Chief Executive Officer at Kamada Ltd. since July 1, 2015. Mr. London served as an Senior Vice President of Business Development at Kamada Ltd.from December 9, 2013 to July 1,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Amir London	Chief Executive Officer	9.3yrs	US$861.00k	0.10% ₪ 1.3m
Chaime Orlev	Chief Financial Officer	1.5yrs	US$509.00k	0.020% ₪ 243.5k
Eran Nir	Chief Operating Officer	8yrs	US$387.00k	0.018% ₪ 217.8k
Jon Knight	Vice President of US Commercial Operations	no data	US$350.00k	Nessun dato
Boris Gorelik	Vice President of Business Development & Strategic Programs	2.4yrs	US$457.00k	Nessun dato
David Tsur	Co-Founder & Independent Deputy Chairman of the Board	9.3yrs	US$300.00k	1.06% ₪ 12.7m
Nir Livneh	VP, General Counsel & Corporate Secretary	1.5yrs	Nessun dato	Nessun dato
Hanni Neheman	Vice President of Marketing & Sales	4.8yrs	Nessun dato	0.0059% ₪ 71.5k
Liron Reshef	Vice President of Human Resources	1.8yrs	Nessun dato	Nessun dato
Shavit Beladev	Vice President of Kamada Plasma	2.4yrs	Nessun dato	0.0060% ₪ 71.6k

2.4yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di KMDA è considerato esperto (durata media dell'incarico 2.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
David Tsur	Co-Founder & Independent Deputy Chairman of the Board	9.3yrs	US$300.00k	1.06% ₪ 12.7m
Leon Recanati	Independent Director	19.5yrs	Nessun dato	3.44% ₪ 41.4m
Ishay Davidi	Independent Director	4.9yrs	Nessun dato	Nessun dato
Lilach Asher-Topilsky	Independent Chairman of the Board	4.9yrs	Nessun dato	Nessun dato
Assaf Itshayek	Independent External Director	1.3yrs	Nessun dato	Nessun dato
Benjamin Dekel	Independent External Director	1.3yrs	Nessun dato	Nessun dato
Lilach Payorski	Independent Director	2.9yrs	Nessun dato	Nessun dato
Karnit Goldwasser	Independent Director	4.9yrs	Nessun dato	Nessun dato
Uri Botzer	Independent Director	1.9yrs	Nessun dato	Nessun dato

4.9yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di KMDA sono considerati esperti (durata media dell'incarico 4.9 anni).

Kamada Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Kamada Ltd., Annual General Meeting, Dec 11, 2024

Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year

Kamada Ltd., Annual General Meeting, Dec 28, 2023

Kamada Ltd. Appoints Uri Botzer as Members of Board of Directors

Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023

We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed

Recent updates

Solid Earnings Reflect Kamada's (TLV:KMDA) Strength As A Business

Third quarter 2024 earnings released: EPS: US$0.07 (vs US$0.07 in 3Q 2023)

Kamada Ltd. to Report Q3, 2024 Results on Nov 13, 2024

Kamada Ltd., Annual General Meeting, Dec 11, 2024

Second quarter 2024 earnings released: EPS: US$0.08 (vs US$0.04 in 2Q 2023)

Kamada Ltd. Provides Earnings Guidance for the Year 2024

Kamada Ltd. to Report Q2, 2024 Results on Aug 14, 2024

First quarter 2024 earnings released

Kamada Ltd. Raises Earnings Guidance for the Year 2024

Kamada Ltd. to Report Q1, 2024 Results on May 08, 2024

Kamada's (TLV:KMDA) Earnings Are Of Questionable Quality

Full year 2023 earnings released: EPS: US$0.17 (vs US$0.052 loss in FY 2022)

Kamada Ltd. Provides Revenue Guidance for the Year 2024

Kamada Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Kamada Ltd. (TLV:KMDA) Held Back By Insufficient Growth Even After Shares Climb 29%

Some Shareholders May find It Hard To Increase Kamada Ltd.'s (TLV:KMDA) CEO Compensation This Year

Investor sentiment improves as stock rises 19%

Third quarter 2023 earnings released: EPS: US$0.07 (vs US$0.011 in 3Q 2022)

Kamada Ltd., Annual General Meeting, Dec 28, 2023

Kamada Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

New minor risk - Shareholder dilution

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.09 loss in 2Q 2022)

Kamada Ltd. to Report Q2, 2023 Results on Aug 16, 2023

First quarter 2023 earnings released: US$0.04 loss per share (vs US$0.04 loss in 1Q 2022)

Kamada Ltd. announced that it expects to receive $59.85 million in funding from First Israel Mezzanine Investors Ltd.

Kamada Ltd. to Report Q1, 2023 Results on May 24, 2023

Kamada Ltd. Announces Receipt of Marketing Authorization for Glassia for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

Kamada Ltd. Announces U.S. FDA Approval of Its Application to Manufacture CYTOGAM At the Company’s Facility in Israel

Full year 2022 earnings released: US$0.05 loss per share (vs US$0.05 loss in FY 2021)

Is Kamada (TLV:KMDA) Using Too Much Debt?

Kamada Ltd. Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® At the Company’s Facility in Israel

Kamada Ltd. Appoints Uri Botzer as Members of Board of Directors

Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023

We Discuss Why Kamada Ltd.'s (TLV:KMDA) CEO Compensation May Be Closely Reviewed

Third quarter 2022 earnings released: EPS: US$0.01 (vs US$0.02 loss in 3Q 2021)

Kamada Ltd. Provides Revenue Guidance for the Fiscal Year 2022

Kamada Ltd. to Report Q3, 2022 Results on Nov 22, 2022

High number of new directors

Kamada Ltd., Annual General Meeting, Dec 22, 2022

Kamada Ltd. Updates on Recent Progress Achieved in Ongoing Pivotal Phase 3 InnovAATe Clinical Trial

Second quarter 2022 earnings released: US$0.09 loss per share (vs US$0.02 profit in 2Q 2021)

Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022

Kamada Ltd. to Report Q2, 2022 Results on Aug 17, 2022

Kamada Ltd. Provides Earnings Guidance for the Full Year of 2022

First quarter 2022 earnings released: US$0.04 loss per share (vs US$0.06 profit in 1Q 2021)

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022

Kamada Ltd. to Report Q1, 2022 Results on May 17, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Kamada Ltd. to Report Q4, 2021 Results on Mar 15, 2022

Kamada Ltd. Acquires Portfolio of Four Plasma-Derived Hyperimmune Commercial Products from Saol Therapeutics

Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint

Kamada Ltd.(TASE:KMDA) dropped from TA-125 Index

Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.08 in 2Q 2020)

Kedrion Biopharma and Kamada Ltd. Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

First quarter 2021 earnings released: EPS US$0.06 (vs US$0.12 in 1Q 2020)

Kamada Ltd. (TASE:KMDA) completed the acquisition of Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc.

New 90-day low: ₪20.12

Investors Who Bought Kamada (TLV:KMDA) Shares Five Years Ago Are Now Up 38%

Full year 2020 earnings released: EPS US$0.39 (vs US$0.55 in FY 2019)

Revenue misses expectations

Investor sentiment improved over the past week

New 90-day high: ₪24.74

Is Kamada Ltd. (TLV:KMDA) Popular Amongst Insiders?

Kamada Ltd. to Report Q4, 2020 Results on Feb 10, 2021

Kamada Ltd. (TASE:KMDA) entered into an agreement to acquire Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc. for $1.6 million.